Personalized medicines necessitate adjustments to established cleanroom procedures. The development of therapies tailored to individual patients introduces complexities that current cleanroom protocols may not fully address. Specifically, the movement toward individualized treatments requires a reevaluation of existing practices within sterile manufacturing environments. Cleanroom protocols, traditionally designed for mass-produced pharmaceuticals, may need to adapt to accommodate the unique requirements of personalized medicines, whose procedures and standards must now evolve.
Newsflash | Powered by GeneOnline AI
Date: May 6, 2025

發佈留言